Detecting ALK Rearrangement with RT-PCR: A Reliable Approach Compared with Next-Generation Sequencing in Patients with NSCLC
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-2000
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Detecting ALK Rearrangement with RT-PCR: A Reliable Approach Compared with Next-Generation Sequencing in Patients with NSCLC ; volume:25 ; number:4 ; day:16 ; month:6 ; year:2021 ; pages:487-494 ; date:7.2021
Molecular diagnosis & therapy ; 25, Heft 4 (16.6.2021), 487-494, 7.2021
- Urheber
-
Kuang, Yukun
Xu, Peihang
Wang, Jiyu
Zheng, Yifan
Sun, Xue
Li, Zimu
Gan, RunJing
Li, Huixia
Guo, Yubiao
Yao, Fei
Zhu, Changbin
Ke, Zunfu
Tang, Kejing
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40291-021-00532-8
- URN
-
urn:nbn:de:101:1-2021101223235752846657
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kuang, Yukun
- Xu, Peihang
- Wang, Jiyu
- Zheng, Yifan
- Sun, Xue
- Li, Zimu
- Gan, RunJing
- Li, Huixia
- Guo, Yubiao
- Yao, Fei
- Zhu, Changbin
- Ke, Zunfu
- Tang, Kejing
- SpringerLink (Online service)
Ähnliche Objekte (12)
ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
Primary Resistance to ALK Inhibitors in a Patient with Nonsmall Cell Lung Cancer with ALK Rearrangement: A Case Report with Review of Literature
Alecensa bei ALK-positivem NSCLC
Central nervous system ALK-negative anaplastic large cell lymphoma with IRF4/DUSP22 rearrangement
Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC
Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
P-glycoprotein confers acquired resistance to 17-DMAG in lung cancers with an ALK rearrangement
Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC
Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression
Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study
Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK
ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
Primary Resistance to ALK Inhibitors in a Patient with Nonsmall Cell Lung Cancer with ALK Rearrangement: A Case Report with Review of Literature
Alecensa bei ALK-positivem NSCLC
Central nervous system ALK-negative anaplastic large cell lymphoma with IRF4/DUSP22 rearrangement
Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC
Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
P-glycoprotein confers acquired resistance to 17-DMAG in lung cancers with an ALK rearrangement
Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC
Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression
Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study
Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK
ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
Primary Resistance to ALK Inhibitors in a Patient with Nonsmall Cell Lung Cancer with ALK Rearrangement: A Case Report with Review of Literature
Alecensa bei ALK-positivem NSCLC
Central nervous system ALK-negative anaplastic large cell lymphoma with IRF4/DUSP22 rearrangement
Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC
Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
P-glycoprotein confers acquired resistance to 17-DMAG in lung cancers with an ALK rearrangement
Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC
Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression
Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study